John,

President Trump’s second term has been lucrative for the whole Trump family, which has raked in BILLIONS over the last year, according to a report from the House Oversight Committee.

One way the Trump family has capitalized on access to power has been through a flurry of new corporate board memberships. Let’s break it down:

The president’s sons, Eric Trump and Donald Trump Jr., have joined the boards of 10 companies since the 2024 election. Two of these companies—Unusual Machines and Credova—appear to have gained an edge with the Trump administration following the addition of his son to their boards, while a third may stand to benefit.

This creates countless potential conflicts of interest for the president as he makes policy decisions that affect those businesses and, therefore, his own family’s net worth.

We’ll break down the details of the benefits those companies received or might receive thanks to Don Jr.’s board membership below. But first, can you donate today to help CREW keep up this critical work? →

Don Jr. joined the advisory board of drone manufacturer Unusual Machines weeks after the 2024 election. The company quickly established itself as a supplier to the U.S. Army in October 2025, delivering an order for 3,500 drone motors and other components. Unusual Machines has also stated that the Army has plans to order 20,000 more components from the company this year. Don Jr. was compensated for his advisory board service with 200,000 shares of Unusual Machines stock.

In December 2024, Don Jr. joined the board of the e-commerce and payments company PublicSquare. In August 2025, the company announced that the Consumer Financial Protection Bureau had closed its years-long investigation into Credova Financial, a subsidiary of PublicSquare accused of violating state consumer protection laws. Don Jr. was compensated more than $3.1 million by Credova’s parent company.

In February 2025, Don Jr. was also named to the board of BlinkRX, a digital pharmacy company. In late July, President Trump sent letters to drug manufacturers directing them to offer direct-to-consumer sales of certain drugs within 60 days. One week later, BlinkRx launched a program that would allow pharmaceutical companies to create platforms to do just that. In September, President Trump announced TrumpRx, a government website planned to launch in 2026 that would steer consumers to purchase prescription drugs directly from manufacturers.

Democratic health committee leaders in the House and Senate sent a letter to BlinkRx raising questions about potential coordination between the administration and the company. BlinkRx responded in a letter that the company first learned about TrumpRx “from press reports” and had “no role in the development” of the announcement.

Even the appearance of preferential treatment by the government toward these companies after they included the Trump family in their dealings undermines public confidence in government decision-making.

The Trump family’s increasingly sprawling business interests risk corrupting public trust in the executive branch. We need to ensure that Trump is putting the American people first, despite his family’s business entanglements.

John, if you believe in transparent, accountable, ethical government—not government sold off to the highest bidder—please donate to help CREW continue its work exposing the truth, uncovering hidden influence and holding the powerful to account →

If you've saved your payment information with ActBlue Express, your tax-deductible donation will go through immediately to ActBlue Charities Inc. and be disbursed to CREW within 30 days:

Thank you,

CREW HQ